-
NR2B as a Therapeutic Target in Parkinson's Disease
… by the loss of striatal dopamine, as well as in the dyskinesias produced by repeated levodopa administration, we … progression of Parkinson’s Disease and in the moderation of dyskinesias associated with long-term levodopa … … Symptoms & Side Effects … Complications of Treatment … Dyskinesia … Glutamate Receptors … Neuropharmacology … …
-
Maintenance of Continuous Plasma Levodopa Levels through Continuous Subcutaneous Carbidopa Administration
… chronic levodopa therapy (such as motor fluctuations and dyskinesias). Current long-acting levodopa products or COMT … dopaminergic infusion therapies has shown that reducing dyskinesias and motor fluctuations can greatly improve … range and patients would experience with less “off” time or dyskinesias. Progress Report In this Phase I/II safety and …
-
Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway
… hampered by serious side effects, including L-DOPA -induced dyskinesias (LID), compulsive behaviors and somnolence. … clinical development. May 2014 … Symptoms & Side Effects … Dyskinesia … Therapeutic Development … Neuropharmacology … …
-
Validation of Enzymatic Activity and Neuropathology in G2019S LRRK2-induced Dopaminergic Neurodegeneration in a Pre-clinical Model of Parkinson's Disease
… essential tools needed to develop this model of PD.’ … Dyskinesia … Clinical Trial … New York … United States … …
-
The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex
… and its associated cognitive phenotype in PD patients. … Dyskinesia … Clinical Trial … North Carolina … United States …
-
Multicenter Clinical Trial of Deep Brain Stimulation in Early Stage Parkinson’s Disease
… launch this large-scale multicenter study. … Epidemiology … Dyskinesia … Clinical Trial … Deep Brain Stimulation … …